SYMPLIFY – assessing a multi-cancer early detection test in individuals referred with signs and symptoms of cancer

Not Applicable

Completed

• Conditions: Early detection of cancer; Cancer

• Registration Number: ISRCTN10226380
• Lead Sponsor: niversity of Oxford

Brief Summary

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37352875/ (added 26/06/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-13
• Study Completion: 2022-11-30
• Last Update Posted: 10 July 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 6238

Inclusion Criteria

1. Participants referred to an RDC or relevant 2WW pathway to rule a cancer diagnosis in or out will be invited to participate in the study.
2. Willing and able to give informed consent for participation in the study.
3. Male or Female, aged 18 years or above.
4. Referred to a RDC or a gynae, lung, upper GI or lower GI cancer 2WW pathway.

Exclusion Criteria

1. Has a history of invasive or haematological malignancy diagnosed within the previous 3 years.
2. Has undergone definitive treatment for invasive or haematological malignancy in the last 3 years (adjuvant hormone therapy is permissible in this context).
3. Is taking cytotoxic or demethylating agents such as methotrexate.
4. Previous or current participation in another GRAIL study. Participation” is defined as having signed consent and provided a blood sample.

Study & Design

• Study Type: Observational
• Study Design: Not specified